GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Total Current Liabilities

Ocean Biomedical (Ocean Biomedical) Total Current Liabilities : $30.85 Mil (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Ocean Biomedical's total current liabilities for the quarter that ended in Sep. 2023 was $30.85

Ocean Biomedical Total Current Liabilities Historical Data

The historical data trend for Ocean Biomedical's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Total Current Liabilities Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
0.23 2.27 0.25 3.46

Ocean Biomedical Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.46 23.43 26.68 30.85

Ocean Biomedical Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Ocean Biomedical's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.314+2.15
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=3.46

Ocean Biomedical's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=16.852+12.051
+Other Current Liabilities+Current Deferred Liabilities
=1.948+0
=30.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Ocean Biomedical Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocean Biomedical (Ocean Biomedical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Total Current Liabilities
Comparable Companies
FIXX CRVS ASMB IOBT HCWB ANEB ALGS ANVS ACET SPRO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
8AW0:Germany
Address
55 Claverick Street, Room 325, Providence, RI, USA, 02903
Website
https://www.oceanbiomedical.com
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
Executives
Robert J Sweeney officer: Chief Accounting Officer 20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey director 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens director C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria officer: Chief Strategy Officer 19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra officer: Chief Financial Officer 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria director C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo director 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc 10 percent owner OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr officer: EVP, Innov./Acad. P'ships Head OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng director, officer: Chief Executive Officer OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc 10 percent owner 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526

Ocean Biomedical (Ocean Biomedical) Headlines

From GuruFocus

Ocean Biomedical's (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean's Program to Address Global and Emerging U.S. Malaria Challenges

By Marketwired • 07-11-2023

Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner

By Marketwired • 10-03-2023

Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund

By Marketwired • 10-04-2023

Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics

By Marketwired • 10-17-2023

Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility

By sperokesalga sperokesalga • 05-16-2023

Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing

By sperokesalga sperokesalga • 06-21-2023

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

By GlobeNewswire • 11-29-2023

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

By sperokesalga sperokesalga • 04-17-2023

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

By Marketwired • 08-01-2023

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

By sperokesalga sperokesalga • 04-25-2023